Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance
Status:
Completed
Trial end date:
2020-04-30
Target enrollment:
Participant gender:
Summary
This open-label, proof-of-principle two center cohort study will evaluate the ability of
autologous hematopoietic stem cell transplantation to induce tolerance in recipients of
deceased or live donor liver transplants (ASCOTT). A maximum of 10 participants will be
entered at a minimum of 3 months post liver transplant. The participants will undergo
autologous hematopoietic stem cell transplants (HSCT) to "re-educate" their immune systems to
accept the graft without the need for long term immunosuppression (tolerance).